Randomized Controlled Trial of the Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer

被引：0
|
作者：
Gogenur, Mikail [1 ]
Gogenur, Ismail [1 ]
机构：
[1] Zealand Univ Hosp, Ctr Surg Sci, Dept Surg, Roskilde, Denmark
来源：
ANNALS OF SURGERY | 2017年 / 266卷 / 06期
关键词：
OPEN SURGERY; ANESTHESIA; REDUCTION; MORTALITY;
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：E105 / E106
页数：2
相关论文
共 50 条
  • [31] Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
    Chen, Xin
    Tu, Junhao
    Xu, Xiaolan
    Gu, Wen
    Qin, Lei
    Qian, Haixin
    Jia, Zhenyu
    Ma, Chuntao
    Xu, Yinkai
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [32] Is adjuvant chemotherapy an option for stage II colon cancer?
    Christophe Tournigand
    Aimery de Gramont
    Nature Reviews Clinical Oncology, 2011, 8 : 574 - 576
  • [33] Is adjuvant chemotherapy an option for stage II colon cancer?
    Tournigand, Christophe
    de Gramont, Aimery
    NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (10) : 574 - 576
  • [34] Multicenter phase II trial of neoadjuvant chemotherapy with mFOLFOX6 for stage II/III rectal cancer with a T3/T4 tumor FACT trial.
    Enomoto, Toshiyuki
    Saida, Yoshihisa
    Takabayashi, Kazuhiro
    Nagao, Jiro
    Koike, Junichi
    Funahashi, Kimihiko
    Yoshimatsu, Kazuhiko
    Yokomizo, Hajime
    Kan, Hayato
    Yamada, Takeshi
    Ishida, Hideyuki
    Ishibashi, Keiichiro
    Katsumata, Kenji
    Hasegawa, Hirotoshi
    Koda, Keiji
    Ochiai, Takumi
    Sakamoto, Kazuhiro
    Ogawa, Shimpei
    Itabashi, Michio
    Kameoka, Shingo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [35] mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial
    Kyung-Ha Lee
    In Jun Yang
    Gi Won Ha
    Jaeim Lee
    Youn Young Park
    Suk Hwan Lee
    Jong Min Lee
    Jung Hoon Bae
    Eun Jung Park
    Hyungjin Kim
    Keun Young Kim
    Sanghyung An
    Ik Yong Kim
    Ji Yeon Kim
    BMC Cancer, 24
  • [36] mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial
    Lee, Kyung-Ha
    Yang, In Jun
    Ha, Gi Won
    Lee, Jaeim
    Park, Youn Young
    Lee, Suk Hwan
    Lee, Jong Min
    Bae, Jung Hoon
    Park, Eun Jung
    Kim, Hyungjin
    Kim, Keun Young
    An, Sanghyung
    Kim, Ik Yong
    Kim, Ji Yeon
    BMC CANCER, 2024, 24 (01)
  • [37] Two phase III studies comparing 6 months of either mFOLFOX6 or XELOX with 3 months of the same regimen as adjuvant chemotherapy in patients with completely resected stage III colon cancer (ACHIEVE) or high-risk stage II colon cancer (ACHIEVE-2).
    Yoshino, Takayuki
    Watanabe, Toshiaki
    Mori, Masaki
    Ohtsu, Atsushi
    Mizushima, Tsunekazu
    Yamazaki, Kentaro
    Sunami, Eiji
    Shirao, Kunlaki
    Sato, Atsushi
    Morita, Satoshi
    Yamanaka, Takeharu
    Gzothey, Axel
    Sargent, Daniel J.
    Sakamoto, Junichi
    Saji, Shigetoyo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [38] Adjuvant chemotherapy for stage III colon cancer in the oldest old
    Abraham, Anasooya
    Habermann, Elizabeth B.
    Rothenberger, David A.
    Kwaan, Mary
    Weinberg, Armin D.
    Parsons, Helen M.
    Gupta, Pankaj
    Al-Refaie, Waddah B.
    CANCER, 2013, 119 (02) : 395 - 403
  • [39] Duration of Adjuvant Chemotherapy for Stage III Colon Cancer REPLY
    Shi, Qian
    Paul, James
    Grothey, Axel
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (04): : 396 - 397
  • [40] Refining the role of adjuvant chemotherapy in stage III colon cancer
    Tanis, Pieter J.
    COLORECTAL DISEASE, 2019, 21 (02) : 135 - 136
12345